Damluji, MD, PhD, MBA Published Mar 29, 2025 The SOUL trial, published in The New England Journal of Medicine on March 29, 2025, provides new evidence that once-daily oral semaglutide reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes and a history of atherosclerotic cardiovascular disease, chronic kidney disease, or both
For certain conditions, and yes, are prescribed for other off-label effects
What that phrase does not mean is illegal, and it does not automatically mean unsafe
Our team of skilled healthcare professionals utilizes premium-quality B12 supplements combined with advanced injection techniques to ensure maximum efficacy
2017;5(4):251 to 260
Understanding GLP-1 Medications and Muscle Loss Challenges GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which naturally regulates blood sugar and appetite